amfAR Issue Brief: Hepatitis C and Drug Pricing - The Need for a Better Balance

In this brief, we review drug pricing for new hepatitis C medications and pose basic questions of fairness and medical ethics. Although we focus on Gilead and its hepatitis C drug sofosbuvir, the issues we highlight are broadly applicable to other manufacturers of hepatitis C medications.